Stock Screener App

Frei -

Installieren

0.8457

9.36% -0.0873

after-market

Handel nachbörslich: .89 0.0443 +5.24%

Karyopharm Therapeutics Inc (KPTI)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Karyopharm Therapeutics Inc Aktie (KPTI) Neueste Nachrichten

Karyopharm Therapeutics Inc. Reports Q3 2024 Earnings - TipRanks

Karyopharm Therapeutics (KPTI) Q3 2024 Earnings Call Transcript - Yahoo Finance

Karyopharm Therapeutics: Q3 Earnings Snapshot - San Francisco Chronicle

Karyopharm Therapeutics (KPTI) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance

Karyopharm Therapeutics Inc (KPTI) Q3 2024 Earnings: EPS Loss of - GuruFocus.com

Karyopharm Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Karyopharm Reports Third Quarter 2024 Financial Results and Highlights Recent Company Progress - PR Newswire

Karyopharm Therapeutics' SWOT analysis: oncology firm's stock faces pivotal year - Investing.com UK

Karyopharm Therapeutics Inc (KPTI) Q3 2024: Everything You Need To Know Ahead Of Earnings - GuruFocus.com

KPTIKaryopharm Therapeutics Inc. Latest Stock News & Market Updates - StockTitan

Karyopharm Therapeutics (KPTI) May Report Negative Earnings: Know the Trend Ahead of Q3 Release - MSN

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PR Newswire

Karyopharm Therapeutics (KPTI) to Release Quarterly Earnings on Tuesday - MarketBeat

Karyopharm Therapeutics' (KPTI) Buy Rating Reiterated at HC Wainwright - MarketBeat

Karyopharm updates SENTRY trial endpoints, eyes 2025 data - Investing.com India

Karyopharm updates SENTRY trial endpoints, eyes 2025 data By Investing.com - Investing.com Canada

Karyopharm gains after changes to late-stage trial - MSN

Karyopharm stock gains as late-stage trial changes (KPTI:NASDAQ) - Seeking Alpha

Karyopharm to Report Third Quarter 2024 Financial Results on November 5, 2024 - StockTitan

Karyopharm Announces Favorable Change in Co-Primary Endpoint for Pivotal Phase 3 SENTRY Trial in Myelofibrosis - StockTitan

Karyopharm to Host Investor Event with Leading Myelofibrosis KOLs and Provide a Favorable Study Design Update on October 31, 2024 - Investor Relations | Karyopharm Therapeutics

Karyopharm Therapeutics (NASDAQ:KPTI) Share Price Passes Below 200 Day Moving AverageHere's What Happened - MarketBeat

Highbridge Capital Management's Strategic Acquisition of Karyopharm Therapeutics Shares - Yahoo Finance

Highbridge Capital Management's Strategic Acquisition of Karyoph - GuruFocus.com

Karyopharm Therapeutics (NASDAQ:KPTI) Shares Cross Above 50-Day Moving AverageShould You Sell? - MarketBeat

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Holdings Lifted by AQR Capital Management LLC - MarketBeat

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat

Karyopharm Therapeutics Inc [KPTI] Records 200-Day SMA of $1.0212 - Knox Daily

Ratios in Focus: Analyzing Karyopharm Therapeutics Inc (KPTI)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex

KPTI’s latest rating updates from top analysts. - Knox Daily

Karyopharm Therapeutics Inc (KPTI) is looking forward to a strong quarter - SETE News

Karyopharm Therapeutics Inc (KPTI) stock analysis: A simple moving average approach - US Post News

Cubist Systematic Strategies LLC Buys New Shares in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) - Defense World

Marshall Wace LLP Decreases Position in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) - Defense World

Cubist Systematic Strategies LLC Takes Position in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) - MarketBeat

Karyopharm Therapeutics Inc [NASDAQ: KPTI] Sees Decrease in Stock Value - Knox Daily

Was Karyopharm Therapeutics Inc (KPTI)’s session last reading good? - US Post News

Monitoring Karyopharm Therapeutics Inc (KPTI) after recent insider movements - Knox Daily

Analyzing the Impact of Earnings Reports on Karyopharm Therapeutics Inc Inc. (KPTI) Price Performance - The InvestChronicle

Why Investors Shouldn't Be Surprised By Karyopharm Therapeutics Inc.'s (NASDAQ:KPTI) Low P/S - Simply Wall St

Financial Snapshot: Analyzing Karyopharm Therapeutics Inc (KPTI)’s Key Ratio Metrics - The Dwinnex

A new trading data show Karyopharm Therapeutics Inc (KPTI) is showing positive returns. - SETE News

Karyopharm Therapeutics' SWOT analysis: pipeline potential drives stock outlook - Investing.com India

Karyopharm Therapeutics' SWOT analysis: pipeline potential drives stock outlook By Investing.com - Investing.com UK

SVP, General Counsel&Secretary Mano Michael sold 3,971 shares of Karyopharm Therapeutics Inc [KPTI] - Knox Daily

Karyopharm Therapeutics Inc (KPTI) Performance and Fundamentals Dashboard tells a completely different story - SETE News

The Globe and Mail - The Globe and Mail

A stock that deserves closer examination: Karyopharm Therapeutics Inc (KPTI) - US Post News

Metric Deep Dive: Understanding Karyopharm Therapeutics Inc (KPTI) Through its Ratios - The Dwinnex

KJTS Group shares climb to near six-week high after contract win - The Edge Malaysia

Market Movers to Watch: Black Diamond (Nasdaq: BDTX), Peraso Inc. (NASDAQ: PRSO), Kaival Brands (NASDAQ: KAVL) among others w/Key Announcements - Barchart

KEC International Shares Surge 3% on Securing Orders Worth Rs 1,003 Crore - EquityPandit

KEC International Boosts Market Presence with Rs 1,003 Crore New Contracts - PUNE.NEWS

KEC International surges 3% after bagging orders worth Rs 1,003 cr; details - Business Standard

India's KEC International rises on 10.03 bln rupee order wins - XM

KEC International shares surge 4% on new orders worth Rs 1,003 crore - Moneycontrol

Acadian Asset Management LLC Invests $167,000 in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) - Defense World

KEC International down 5% as CARE Ratings downgrades co's bank facilities - Business Standard

KEC International shares drop 4% after credit rating downgrade by CARE - Business Upturn

5:1 Stock Split Announced by This Multibagger Smallcap Company- Stock Hits 52-Week High Today, Gains Over 1,000 Per cent Returns in Just 1 Year! - Dalal Street Investment Journal

KHPT unveils ACE Market IPO prospectus to raise up to RM29 mil - The Edge Malaysia

Karyopharm faces Nasdaq delisting over share price woes By Investing.com - Investing.com Australia

Karyopharm faces Nasdaq delisting over share price woes - Investing.com India

INCY

$77.28

2.02%

SMMT

$20.39

2.15%

UTHR

$382.77

1.58%

MRNA

$53.29

0.47%

BGNE

$208.03

0.38%

BNTX

$110.97

1.84%

In Yahoo öffnen | In Google öffnen | In Finviz öffnen | Open in MarketWatch | Open in EDGAR | Open in Reuters